Rigel Pharmaceuticals Inc logo

RIGL - Rigel Pharmaceuticals Inc Share Price

$3.71 -0.0  -0.3%

Last Trade - 21/09/21

Mid Cap
Market Cap £465.4m
Enterprise Value £367.6m
Revenue £105.5m
Position in Universe 3405th / 7157
Unlock RIGL Revenue
Relative Strength (%)
1m +2.99%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -32.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
28.9 20.4 4.48 44.5 59.3 108.6 159.2 122.2 +30.3%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, RigelPharmaceuticals, Inc. revenues increased 49% to $107.3M.Net income increased from $3.7M to $25.7M. Revenues reflectProduct sales, net increase of 42% to $82.7M, Contractrevenues from collaborations increase of 17% to $16.1M. Netincome benefited from Stock-based Compensation in R&Ddecrease of 3% to $1.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RIGL Revenue Unlock RIGL Revenue

Net Income

RIGL Net Income Unlock RIGL Revenue

Normalised EPS

RIGL Normalised EPS Unlock RIGL Revenue

PE Ratio Range

RIGL PE Ratio Range Unlock RIGL Revenue

Dividend Yield Range

RIGL Dividend Yield Range Unlock RIGL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RIGL EPS Forecasts Unlock RIGL Revenue
Profile Summary

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated June 14, 1996
Public Since November 29, 2000
No. of Shareholders: 90
No. of Employees: 169
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 170,850,306
Free Float (0.0%)
Eligible for
RIGL Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RIGL
Upcoming Events for RIGL
Tuesday 28th September, 2021
Rigel Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)
Wednesday 3rd November, 2021 Estimate
Q3 2021 Rigel Pharmaceuticals Inc Earnings Release
Monday 28th February, 2022 Estimate
Q4 2021 Rigel Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Rigel Pharmaceuticals Inc
What is the Rigel Pharmaceuticals Inc share price?

As of 21/09/21, shares in Rigel Pharmaceuticals Inc are trading at $3.71, giving the company a market capitalisation of £465.4m. This share price information is delayed by 15 minutes.

How has the Rigel Pharmaceuticals Inc share price performed this year?

Shares in Rigel Pharmaceuticals Inc are currently trading at $3.71 and the price has moved by 46.46% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Rigel Pharmaceuticals Inc price has moved by 8.4% over the past year.

What are the analyst and broker recommendations for Rigel Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Rigel Pharmaceuticals Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Rigel Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Rigel Pharmaceuticals Inc next release its financial results?

Rigel Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Rigel Pharmaceuticals Inc dividend yield?

Rigel Pharmaceuticals Inc does not currently pay a dividend.

Does Rigel Pharmaceuticals Inc pay a dividend?

Rigel Pharmaceuticals Inc does not currently pay a dividend.

When does Rigel Pharmaceuticals Inc next pay dividends?

Rigel Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Rigel Pharmaceuticals Inc shares?

To buy shares in Rigel Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Rigel Pharmaceuticals Inc?

Shares in Rigel Pharmaceuticals Inc are currently trading at $3.71, giving the company a market capitalisation of £465.4m.

Where are Rigel Pharmaceuticals Inc shares listed? Where are Rigel Pharmaceuticals Inc shares listed?

Here are the trading details for Rigel Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: RIGL
What kind of share is Rigel Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Rigel Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Rigel Pharmaceuticals Inc share price forecast 2021?

Shares in Rigel Pharmaceuticals Inc are currently priced at $3.71. At that level they are trading at 0.124% discount to the analyst consensus target price of 0.00.

Analysts covering Rigel Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.035 for the next financial year.

How can I tell whether the Rigel Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rigel Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -5.18%. At the current price of $3.71, shares in Rigel Pharmaceuticals Inc are trading at -3.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Rigel Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Rigel Pharmaceuticals Inc.

Who are the key directors of Rigel Pharmaceuticals Inc?

Rigel Pharmaceuticals Inc's management team is headed by:

Raul Rodriguez - PRE
Dolly Vance - EVP
Gary Lyons - NEC
Bradford Goodwin - IND
Keith Katkin - IND
Brian Kotzin - IND
Dean Schorno - CFO
Wolfgang Dummer - EVP
David Santos - EVP
Alison Hannah - DRC
Who are the major shareholders of Rigel Pharmaceuticals Inc?

Here are the top five shareholders of Rigel Pharmaceuticals Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 14.94% (25.5m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 8% (13.7m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 6.26% (10.7m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 5.77% (9.87m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.31% (9.08m shares)
Similar to RIGL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.